*仅供医学专业人士阅读参考说到“免疫治疗进展有限”的常见癌症，大家的第一反应会是什么？如果回答是肠癌、胰腺癌、卵巢癌那当然都算正解，但奇点糕要补充一个可能常常被忽略的存在——乳腺癌：虽说在HER2阳性和三阴性乳腺癌治疗中，免疫治疗确实有着不错的效果， ...
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
这是一例绝经前 HR+/HER- 晚期乳腺癌患者，该患者还伴有破溃、广泛骨转移和胸膜转移，经过八周期的化疗后胸部肿块明显缩小，骨转移病灶趋于稳定。考虑到患者较为年轻（41 ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
5 天on MSN
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...
Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈